Related content

ReadMax—a novel reading and scoring approach for EGFR gene copy number to predict therapeutic benefit of erlotinib treatment in EGFR wild‐type non‐small‐cell lung cancer

By  

The Journal Of Pathology: Clinical Research, Vol. 1, Iss. 3, 2015-06 ,pp. : 134-143

John Wiley & Sons Inc

Access to resources Recommend Favorite

Therapeutic cancer vaccines in the treatment of non-small-cell lung cancer

By Limacher Jean-Marc   Spring-Giusti Clémentine   Bellon Nadine   Ancian Philippe   Rooke Ronald   Bonnefoy Jean-Yves  

Expert Review of Vaccines, Vol. 12, Iss. 3, 2013-03 ,pp. : 263-270

Informa Healthcare

Access to resources Recommend Favorite

Phase II study of erlotinib for previously treated patients with EGFR wildtype nonsmallcell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System

By                      

Molecular and Clinical Oncology, Vol. 2, Iss. 6, 2014-01 ,pp. : 991-996

Spandidos Publications

Access to resources Recommend Favorite

Assessment of DDR2, BRAF, EGFR and KRAS mutations as therapeutic targets in non-adenocarcinoma lung cancer patients

By                      

Molecular and Clinical Oncology, Vol. 2, Iss. 5, 2014-01 ,pp. : 714-718

Spandidos Publications

Access to resources Recommend Favorite

Cyclooxygenase2 inhibitors for nonsmallcell lung cancer: A phase II trial and literature review

By                        

Molecular and Clinical Oncology, Vol. 2, Iss. 5, 2014-01 ,pp. : 744-750

Spandidos Publications

Access to resources Recommend Favorite